NIH researchers identify potential new antiviral drug for COVID-19
- Details
- Category: Research
The experimental drug TEMPOL may be a promising oral antiviral treatment for COVID-19, suggests a study of cell cultures by researchers at the National Institutes of Health. TEMPOL can limit SARS-CoV-2 infection by impairing the activity of a viral enzyme called RNA replicase. The work was led by researchers at NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The study appears in Science.
How to obtain immune bovine milk to strengthen the body against COVID-19
- Details
- Category: Research
Physiologically, milk contains biocomponents that are highly protective against infections. In light of this, the AGR-149-Infectious Diseases group at the University of Cordoba's Department of Animal Health is doing research that focuses on cow's milk as a possible source of COVID-19 control. The results have been published, partially, in the journal Frontiers in Immunology.
New study may help explain low oxygen levels in COVID-19 patients
- Details
- Category: Research
A new study published in the journal Stem Cell Reports by University of Alberta researchers is shedding light on why many COVID-19 patients, even those not in hospital, are suffering from hypoxia--a potentially dangerous condition in which there is decreased oxygenation in the body's tissues. The study also shows why the anti-inflammatory drug dexamethasone has been an effective treatment for those with the virus.
Parler provided echo chamber for vaccine misinformation, conspiracy theories
- Details
- Category: Research
In the early days of COVID-19 vaccine development, a new social media platform provided a place for like-minded people to discuss vaccines, share misinformation and speculate about the motivations for its development. A new study from the University of Kansas shows people flocked to Parler to discuss the vaccines in an echo chamber-type environment, and those conversations can shed light about how to communicate about vaccine efficacy during health crises.
Penn researchers discover drug that blocks multiple SARS-CoV-2 variants in mice
- Details
- Category: Research
The drug diABZI - which activates the body's innate immune response - was highly effective in preventing severe COVID-19 in mice that were infected with SARS-CoV-2, according to scientists in the Perelman School of Medicine at the University of Pennsylvania. The findings, published this month in Science Immunology, suggest that diABZI could also treat other respiratory coronaviruses.
Nearly half of COVID-19 patients left hospital in worse physical condition
- Details
- Category: Research
Over a year after the novel coronavirus cemented its grip on the world, much of the conversation surrounding the disease remains simple: how many people died and how many survived?
But researchers at Michigan Medicine say a devastating side effect lurks, underreported, between those extremes - the loss of ability caused by the virus.
Why are some COVID-19 vaccines working better for men than women?
- Details
- Category: Research
MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine.
If there's one take-home message for the general public about the coronavirus vaccines approved in the U.S., it's that they are remarkably effective.
More Pharma News ...
- Rogue antibodies wreak havoc in severe COVID-19 cases
- COVID-19 monoclonal antibodies reduce risk of hospitalization and death
- New vaccine platform: 'Two-one replicon-and-VLP-minispike vaccine' against COVID-19
- COVID-19 mRNA vaccines are immunogenic in pregnant and lactating women
- Major differences in COVID patient care caused by insufficient data, misleading advice
- Researchers develop better way to determine safe drug doses for children
- Our immune systems blanket the SARS-CoV-2 spike protein with antibodies